"Working with the FDA, we intend to find a path forward for a patient population that has waited too long," said Lisa Ricciardi, president and CEO. "Our ultimate goal is to provide patients and their families with a durable treatment option for DLB psychosis that actually slows the progression of hallucinations and delusions." About Cognition Therapeutics Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for deva ...